Why Medtronic Fell by Almost 6% on Monday

·2-min read
Why Medtronic Fell by Almost 6% on Monday

The company released a discouraging business update after market hours on Friday, and its stock took it on the chin the following trading day. In that update, Medtronic said that a clinical trial of its Symplicity Renal Denervation System to lower blood pressure in hypertension patients will continue for an unspecified length of time. In Medtronic's words, the monitoring board "has recommended that clinical trial enrollment continue as planned, until the full, predefined sample size is reached."

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting